| Purity | ≥99% |
| Molecular Weight | 5,135.9 Da |
| Category | GHRH analog / Growth hormone-releasing factor (GRF) analog |
| Sequence | N-(trans-3-hexenoyl)-[Tyr¹]-hGRF(1–44) amide — a 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification (CAS 218949-48-5) |
TESA
A stabilised GHRH(1-44) analog carrying an N-terminal trans-3-hexenoyl modification.
Starting from $95.99
| Qty | Per vial | Discount |
|---|---|---|
| 1 | $95.99 | — |
| 3 | $86.39 | 10% off |
| 5 | $81.59 | 15% off |
| 10 | $74.87 | 22% off |
For research use only. Not for human consumption.
Needs reconstituting
Supplied as lyophilised powder. Reconstitution Liquid 10 mL · $19.99
Storage Conditions
Store lyophilized powder at −20 °C. After reconstitution, store at 4 °C and use within 28 days. Avoid repeated freeze-thaw cycles.
Overview
TESA is a 44-residue analog of growth hormone-releasing factor. The N-terminal modification protects it from rapid enzymatic cleavage, which is the structural difference from the unmodified releasing factor.
Research Areas
- GHRH receptor binding
- Enzymatic-stability and N-terminal modification chemistry
- Pituitary cell-culture model systems
- IGF-1 axis assays
Reviews
No reviews yet — be the first to share your research experience.
Research use only. This product is intended for in vitro and laboratory research purposes only. It is not approved by the FDA for human or veterinary use. It is not a drug, food, or cosmetic, and may not be misbranded, misused, or sold for purposes other than research.
All information provided is for research and educational purposes only and does not constitute medical advice.